Related Experiment Videos
Ki-67 as a marker for cell cycle regulation by interferon
D Lundblad1, G Landberg, G Roos
1Institute of Applied Cell and Molecular Biology, University of Umeå, Sweden.
Anticancer Research
|November 1, 1991
Summary
Interferon (IFN) treatment reduced Ki-67 expression in some cancer cells but not others. Ki-67 antigen is not a reliable marker for monitoring clinical effects of IFN therapy.
Area of Science:
- Cell biology
- Immunology
- Oncology
Background:
- Interferon (IFN) is a crucial cytokine in immune response and cancer therapy.
- Ki-67 is a nuclear antigen commonly used as a marker for cell proliferation.
Purpose of the Study:
- To investigate the effect of interferon on Ki-67 expression in different cancer cell lines.
- To determine if Ki-67 can serve as a reliable biomarker for interferon treatment efficacy.
Main Methods:
- Treatment of IFN-sensitive (Daudi, 251 MG) and IFN-resistant (Namalwa) cell lines with interferon.
- Analysis of Ki-67 expression and cell cycle distribution using flow cytometry.
- Induction of cell cycle arrest via serum deprivation and restimulation.
Main Results:
- IFN treatment decreased Ki-67 expression in GO/G1-arrested Daudi cells, correlating with growth arrest.
- No significant change in Ki-67 expression was observed in IFN-resistant Namalwa cells or S-phase-arrested 251 MG cells.
- Serum deprivation abolished Ki-67 expression in 251 MG cells, with expression resuming upon restimulation and S-phase entry.
Conclusions:
- Ki-67 antigen downregulation is cell-cycle and IFN-sensitivity dependent.
- Ki-67 is not a universally reliable marker for monitoring clinical responses to interferon therapy across all cancer types.